News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III (World)
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Cipher Pharma (DND.TO) Announces Successful Completion Of Second Phase III For Ozenoxacin 7/30/2015
Sanofi (SNY)'s Lixilan Hits Phase III Goal 7/29/2015
AcelRx (ACRX) Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-To-Severe Post-Operative Pain In Adult Patients 7/24/2015
As Biogen (BIIB), Eli Lilly (LLY) Fall Short, Roche (RHHBY) Intensifies Work on Two Alzheimer's Drugs 7/23/2015
PharmaMar S.A. Announces License Agreement With TTY Biopharm For APLIDIN (plitidepsin) In Hematological Cancers 7/23/2015
AstraZeneca PLC (AZN)'s Selumetinib Flunks Phase III Eye Cancer Study 7/22/2015
BioTie Therapies Corp. Announces Start Of Tozadenant Phase 3 Study In Parkinson's Disease 7/21/2015
Onxeo: Update On ReLive, Livatag International Phase III Clinical Trial In HCC 7/21/2015
Telesta Therapeutics Announces South Korean Partnership For MCNA & Concurrent Private Placement 7/20/2015
Pierre Fabre Release: Bladder Cancer Patients And Doctors Disappointed By Scottish Medicines Consortium's Negative Decision On Javlor (Vinflunine As Ditartrate) For The Treatment Of Adult Patients 7/13/2015
Regeneron (REGN), Sanofi (SAN.PA)'s Praluent Delivers in Late Stage Trial 7/9/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
AstraZeneca PLC (AZN) And Ironwood (IRWD) Report Positive Top-Line Data From Phase III IBS-C Trial Designed To Support Linaclotide Approval In China 7/8/2015
Boehringer Ingelheim Release: Phase III Data Published In The Lancet Oncology Shows A Significant Overall Survival Benefit Of Giotrif (Afatinib) Compared To Tarceva(Erlotinib) 7/6/2015
RedHill Biopharma Ltd. (RDHL) Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104 7/6/2015
AEterna Zentaris (AEZS) Completes Patient Recruitment For ZoptEC Phase 3 Study With Zoptarelin Doxorubicin In Advanced Endometrial Cancer 6/30/2015
PharmaMar S.A. Initiates The Phase III Study CORAIL For The Anticancer Agent PM1183 In Patients With Platinum-Resistant Ovarian Cancer 6/29/2015
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Oculopharyngeal Muscular Dystrophy 6/25/2015
AEterna Zentaris (AEZS) Announces Selection Of ErgoMed To Conduct Confirmatory Phase 3 Clinical Trial Of Macrilen In AGHD 6/25/2015
CSL Behring Presents rIX-FP For Hemophilia B Phase III Data Evaluating Efficacy, Safety And Improved Dosing At ISTH 2015 6/25/2015
Nuvo Research Inc. (NRI.TO) Provides Update On International Licensing Of Pennsaid 2% 6/24/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer's Disease 6/24/2015
Novo Nordisk A/S (NVO) Release: In A Phase 3 Trial, Novoeight(Antihemophilic Factor [Recombinant]) Provided Long-Term Efficacy And Safety In The Prophylaxis And Treatment Of Bleeds In People With Hemophilia A 6/24/2015
Boehringer Ingelheim Phase III Pradax Anticoagulant Antidote Study Meets Primary Endpoints 6/22/2015
Resverlogix (RVX.TO) Officially Attains Phase 3 Status With A European Regulatory Authority 6/22/2015
MedDay Reports Additional Positive Data Of Its Pivotal Phase III Study With MD1003 In Patients With Progressive Multiple Sclerosis 6/19/2015
Eli Lilly (LLY) Release: CYRAMZA (ramucirumab) Hepatocellular Carcinoma Data Published By The Lancet Oncology 6/19/2015
RedHill Biopharma Ltd. (RDHL) Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease 6/16/2015
BioBlast Pharma (ORPN) Announces The Start Of A Phase III Study For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 6/15/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Cogenzia COACT-2 Phase III Study For The Treatment Of Diabetic Foot Infection 6/15/2015
RedHill Biopharma Ltd. (RDHL) To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection 6/15/2015
RedHill Biopharma Ltd. (RDHL) Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection 6/15/2015
CTI BioPharma Release: Pacritinib Phase III Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis 6/12/2015
Genentech (RHHBY) Wins Breakthrough Nod From FDA for Systemic Sclerosis Treatment 6/11/2015
GW Pharma (GWPH) Initiates Second Phase III Pivotal Study Of Epidiolex (CBD) In Lennox-Gastaut Syndrome 6/11/2015
Alkermes (ALKS) Release: Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published In Journal Of Clinical Psychiatry 6/10/2015
Biogen (BIIB) And Samsung Bioepis Announce New Data For Three Anti-TNF Biosimilar Development Candidates At EULAR 2015 Congress 6/10/2015
Celgene (CELG) Release: Oral Presentation Evaluating Pooled Data On OTEZLA (Apremilast) For Long-Term Improvements In Enthesitis And Dactylitis To Be Presented At EULAR 6/10/2015
Merck & Co. (MRK) And Samsung Bioepis Announce Pivotal Phase III Studies For Investigational Biosimilars SB4, Enbrel (Etanercept), And SB2, Remicade (Infliximab), Met Primary Endpoints 6/10/2015
FDA Agrees With OncoGenex Pharmaceuticals Inc. (OGXI)' Phase 3 AFFINITY Protocol Amendment 6/10/2015
New Data Shows LEO Pharma A/S Investigational Psoriasis Treatment, Enstilar, Provides Rapid Itch Relief For Psoriasis Patients 6/10/2015
DalCor Pharma Licenses A Late-Stage Investigational Cardiovascular Drug Following Major Discovery By Montreal Heart Institute Scientists 6/8/2015
RedHill Biopharma Ltd. (RDHL) Completes Treatment Of Last Patient With RHB-105 In Phase III Study 6/8/2015
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Clinical Development Program Evaluating JZP-110 As A Potential Treatment Of Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy Or With Obstructive Sleep Apnea (OSA) 6/8/2015
AstraZeneca PLC (AZN)'s Booming Immuno-Onco Pipeline Validates Rebuffing Pfizer (PFE) 6/5/2015
ALK-Abello A/S Announces Top-Line Results From Its Partner Merck & Co. (MRK)'s North American Phase III Trial Of House Dust Mite SLIT-Tablet 6/4/2015
AstraZeneca PLC (AZN) Gets Closer to a Decision on Suicide-Linked Drug, CEO Says 6/3/2015
RedHill Biopharma Ltd. (RDHL) Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results 6/3/2015
Boehringer Ingelheim’s Vargatef (Nintedanib) In Combination With Docetaxel Is Recommended As A Treatment Option Within Its Marketing Authorisation For Patents With A Common Type Of Lung Cancer 6/2/2015
ASCO15: ERYtech Pharma Reported Full GRASPA Phase III Results In ALL And Provided Update On AML Phase IIb At ASCO 6/2/2015
NeuroVive: Neurovive Reports Topline Results Of Phase III CIRCUS Study In Acute Myocardial Infarction 6/1/2015
ASCO15: Boehringer Ingelheim Release: Superior Overall Survival For Afatinib Compared To Erlotinib Demonstrated In Head-To-Head Trial In Patients With Previously Treated Advanced Squamous Cell Carcinoma Of The Lung 6/1/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan 5/27/2015
BioTie Therapies Corp. Announces Agreement With FDA On A Special Protocol Assessment For Tozadenant Phase 3 Study 5/26/2015
Juventas Therapeutics, Inc. Presents New 12-Month Data Demonstrating Single Administration Of JVS-100 Improves Cardiac And Clinical Status In Patients With Severe Ischemic Heart Failure One Year After Treatment 5/26/2015
AEterna Zentaris (AEZS)' Confirmatory Phase 3 Study for Macrilen In AGHD Meets European Medicines Agency's Study-Design Expectations 5/26/2015
Cardiorentis Completes Enrollment In Pivotal Phase III Clinical Trial Of Ularitide For Acute Heart Failure 5/22/2015
IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA 5/21/2015
Boehringer Ingelheim Release: New Data Show Benefit Of Tiotropium/Olodaterol Respimat From The Start Of COPD Maintenance Therapy1,2,3 5/20/2015
Debiopharm Announces Phase III Positive Results For Triptorelin 6-Month Formulation In The Management Of Central Precocious Puberty (CPP) 5/19/2015
RedHill Biopharma Ltd. (RDHL)'s Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market 5/18/2015
Innocoll, Inc. (INNL) Announces First Patient Dosed In The Cogenzia COACT-1 Phase III Study For The Treatment Of Diabetic Foot Infection 5/15/2015
Endo Pharmaceuticals (ENDP) And BioDelivery Sciences International (BDSI) Present Pivotal Data From Two Phase 3 Trials Demonstrating Safety And Efficacy Of Buprenorphine Hcl Buccal Film For The Management Of Chronic Pain 5/15/2015
Bavarian Nordic (BAVA.CO) Announces Positive Results From Two Pivotal Clinical Studies Of IMVAMUNE Smallpox Vaccine 5/13/2015
Chiasma Announces New Data For Investigational Octreotide Capsules To Be Presented At ECE 2015 5/11/2015
RedHill Biopharma Ltd. (RDHL) To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study 5/7/2015
ViiV Healthcare Begins Phase III Programme With dolutegravir/rilpivirine Combination For HIV Maintenance Therapy 5/6/2015
Indivior PLC Announces Positive Top-Line Results From Pivotal Phase 3 Trial Of RBP-7000 In Schizophrenia 5/5/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Demonstrates Improved Pharmacokinetic Profile In African-American Transplant Recipients 5/4/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Custirsen Phase 3 "ENSPIRIT Trial Update 4/30/2015
AstraZeneca PLC (AZN) Release: Selumetinib Granted Orphan Drug Designation By FDA 4/29/2015
RedHill Biopharma Ltd. (RDHL) Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection 4/27/2015
Can-Fite BioPharma (CFBI) Reports Positive Results From Further Analysis Of Phase II/III Psoriasis Trial 4/27/2015
MedDay Reports Positive Pivotal Phase III Study Results With MD1003 In Patients With Progressive Multiple Sclerosis 4/24/2015
Janssen Announces SVR12 Rates With Twelve Weeks Of Treatment With All-Oral, Once-Daily Regimen Of Simeprevir Plus Sofosbuvir In Genotype 1 HCV Patients With And Without Cirrhosis 4/23/2015
Janssen Sciences Ireland UC Announces SVR12 Rates With Twelve Weeks Of Treatment With All-Oral, Once-Daily Regimen Of Simeprevir ? Plus Sofosbuvir ? In Genotype 1 HCV Patients With And Without Cirrhosis 4/23/2015
Medivir AB (MVRBF): Data From OPTIMIST Trials Show SVR12 Rates Of 97 Percent In HCV Patients Without Cirrhosis And 84 Percent In HCV Patients With Cirrhosis 4/23/2015
GW Pharmaceuticals (GWPH) Initiates Second Phase 3 Pivotal Trial For Epidiolex In Dravet Syndrome 4/21/2015
Global Strategic Partners Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) nitiate Phase III Study With Avelumab* In Patients With Stage IIIb/IV Non-Small Cell Lung Cancer 4/20/2015
Bio Products Laboratory, Ltd. Announces Results From Phase III Registration Study Of Its Factor X Coagulation Product 4/20/2015
Pembrolizumab, Merck & Co. (MRK)'s Investigational Anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab, An Anti-CTLA-4 Therapy, In A Phase 3 Study Of Patients With Advanced Melanoma 4/20/2015
MediWound (MDWD) Initiates U.S. Phase 3 Trial With NexoBrid To Treat Severe Burns 4/20/2015
Ipsen (IPN.PA), Active Biotech AB (BTPC) Plummet As Prostate Cancer Drug Flunks Late-Stage Trial 4/17/2015
MedDay Announces Its Pivotal Phase III Study Of MD1003 In Patients With Progressive Multiple Sclerosis Meets Primary Endpoint 4/17/2015
H. Lundbeck A/S (LUN.CO) and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 4/17/2015
TRANSGENE (ENX:TNG): Agreement With FDA Announced For Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
AbbVie (ABBV)'s Investigational Chronic Hepatitis C Treatment Granted Priority Review In Japan 4/16/2015
AEterna Zentaris (AEZS) Files Additional Patent Application To Strengthen IP Protection Of Zoptarelin Doxorubicin 4/16/2015
CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot (DFU) And Ulcus Cruris (VLU) Indications 4/15/2015
Heart Metabolics Limited And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
DBV Tech Nabs FDA Breakthrough Status for Peanut Allergy Patch 4/13/2015
Horizon Pharma (HZNP) Receives FDA Fast Track Designation For ACTIMMUNE In The Treatment Of Friedreich's Ataxia 4/10/2015
Mesoblast Limited (MSB.AX) Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency 4/8/2015
MedDay Provides Update On Pioneering Pivotal Phase III Study Design In Progressive Multiple Sclerosis 4/7/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Thrasos Scores $21M to Complete Phase II THR-184, Expands Renal Portfolio 4/1/2015
Pivotal Pharmacokinetic Study Of Innocoll, Inc. (INNL)'s Xaracoll(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain 4/1/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/30/2015
Can-Fite BioPharma (CFBI) PhII/III: CF101 Did Not Achieve Primary Endpoint 3/30/2015
Cardio3 BioSciences Successfully Completes Futility Analysis Of Lead Cardiac Cell Therapy, C-Cure(R) 3/30/2015
Teva (TEVA) Reinforces Leadership Position In CNS With Acquisition Of Auspex Pharmaceuticals (ASPX) 3/30/2015
Galderma Announces Positive Outcome Of European Decentralised Procedure For Approval Of Soolantra (Ivermectin) Cream 10mg/G For Rosacea Patients 3/27/2015
European Medicines Agency Release: Accelerated Assessment Fast-Tracks Lenvima To Benefit Patients With Thyroid Cancer 3/27/2015
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015
ThromboGenics NV (TBGNF) Announces Positive Topline Results From OASIS Study 3/24/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Chooses PharmaCell As Contract Manufacturing Partner For Its Phase III Program In Europe 3/20/2015
AstraZeneca PLC (AZN) Two-in-One Lung Drug Succeeds in Phase III Trial 3/19/2015
Sanofi (SAN.PA) Test Shows Lixisenatide Doesn't Up Cardiovascular Risk 3/19/2015
New Cholesterol Drugs From Amgen (AMGN), Sanofi (SAN.PA), Regeneron (REGN) Cut Heart Risks in Half But Questions Remain 3/18/2015
Lexicon Pharmaceuticals, Inc. (LXRX) And Ipsen (IPN.PA) Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada 3/18/2015
AstraZeneca PLC (AZN) Announces Positive Phase III Top-Line Results For PT003 From PINNACLE 1 And PINNACLE 2 Studies In COPD 3/18/2015
QIAGEN N.V. (QGEN) Expands Leadership In Liquid Biopsies With New Circulating Tumor Cell Technology For Development Of Companion Diagnostics 3/17/2015
Sinovac Biotech Ltd. (SVA) Provides Updates On Pipeline Vaccines 3/17/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
PharmaEssentia And AOP Orphan Announce Completion Of Recruitment Of Pivotal Phase III Trial PROUD-PV 3/11/2015
Takeda (TKPYY) Announces Publication In The Lancet Of A Post Hoc Analysis Of Data From The EXAMINE Cardiovascular Safety Outcomes Trial 3/10/2015
Auris Medical AG (EARS) Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101 3/10/2015
Trimel Pharmaceuticals (TRL.TO) Announces Natesto Abstract Presentation At The 2015 Endocrine Society Annual Meeting 3/9/2015
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa 3/9/2015
CytoTools: European Trials On Diabetic Foot And Ulcus Cruris (Leg Ulcers) On Schedule - Delay In The Market Approval For The Wound Healing Agent Dermapro In India 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera 3/5/2015
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Teva Pharmaceutical Industries (TEVA) Release: The Lancet Respiratory Medicine And AAAAI Publish Positive Data From Phase 3 Trials Of Teva’s Reslizumab For The Treatment Of Moderate To Severe Asthma In Patients With Elevated Blood Eosinophils 2/24/2015
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015
BioTie Therapies Corp. Provides Portfolio Update On Tozadenant 2/20/2015
Takeda (TKPYY) Lung Cancer Drug Motesanib Flunks Late Stage Trial 2/19/2015
Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/19/2015
Sanofi (SAN.PA)'s Cerdelga Shows Promise in Late Stage Trial 2/18/2015
Takeda (TKPYY) Announces Phase 3 MONET-A Study Evaluating Motesanib (AMG 706) In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoin 2/17/2015
Improved Survival In Children With Graft Versus Host Disease Who Respond To Mesoblast Limited (MSB.AX)'s Cell Therapy 2/16/2015
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Start Of Phase 3 Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI For COPD 2/9/2015
GlaxoSmithKline (GSK) Touts Positive Data From Phase III COMBI-D Study 2/6/2015
Daiichi Sankyo, Inc. (4568.t) Announces First Patients In Large-Scale, Multi-National Phase 3 Clinical Programs For Mirogabalin 2/4/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 2/3/2015
OSE Pharma Collaboration For Cancer Trial 1/29/2015
RedHill Biopharma Ltd. (RDHL) Provides Update On Progress With RHB-104 Ongoing Phase 3 Program For Crohn's Disease Following FDA Meeting 1/29/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 1/26/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Actavis (ACT), Gedeon Richter Ltd. (RIG2.F) Say Key Drug Cariprazine Effective on Schizophrenia Relapse 1/20/2015
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015
AB Science (AB.PA): The Data and Safety Monitoring Board Recommends The Continuation Of Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis 1/13/2015
Pharmamar Will Start A Phase 3 Study Of PM1183 In Combination With Doxorubicin In Relapsed SCLC 1/13/2015
The Lancet Oncology Publishes Phase III Data Showing Giotrif® (Afatinib*) Significantly Extended Overall Survival Of Lung Cancer Patients With The Most Common EGFR Mutation Over Chemotherapy 1/12/2015
Shield Therapeutics Announces The Publication Of The AEGIS Feraccru Phase 3 Pivotal Trial Manuscript In The Inflammatory Bowel Disease Journal 1/9/2015
GW Pharmaceuticals (GWPH) And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials 1/8/2015
Dermira And UCB SA Announce Start Of Phase 3 Program For CIMZIA® (Certolizumab Pegol) In Psoriasis 1/8/2015
Novartis AG (NVS) Announces Robust Phase 3 Results For QVA149 And NVA237 And Submits Regulatory Applications To U.S. FDA 1/8/2015
Alkermes plc (ALKS) Announces Positive Results From Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 1/6/2015
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study 12/19/2014
Cardio3 BioSciences Announces The Enrolment Of The 240th Patient For Its CHART-1 Phase 3 Clinical Trial For The Treatment Of Heart Failure 12/19/2014
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
Hutchison Medipharma Starts Phase III Trial Of Cancer Drug 12/18/2014
LFB S.A. Announces Achievement Of Patient Enrollment Target For Persept 1 Program For The Evaluation Of Recombinant Factor Seven Efficacy By Prospective Clinical Trials 12/18/2014
Pivotal Phase 3 Study Of GlaxoSmithKline (GSK) Shingles Candidate Vaccine Meets Its Primary Endpoint 12/18/2014
RedHill Biopharma Ltd. (RDHL) Announces First Patients Enrolled In The Phase 3 Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis 12/17/2014
Head-To-Head Psoriasis Study Demonstrates Superiority Of Novartis AG (NVS) Cosentyx™ To Stelara® In Clearing Skin 12/12/2014
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014
BeyondSpring To Start China-U.S. Phase 3 Trial Of Novel Cancer Drug 12/12/2014
Phase 3 Results From German Breast Group (GBG) Demonstrates Superior Activity In High Risk Early Breast Cancer For Nab-Paclitaxel (Abraxane®) Vs. Solvent-Based Paclitaxel 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 12/11/2014
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014
Vectura Group plc (VEC.L)’s Investigational Drug/Device Combination VR475 Met Primary Endpoint And Has Shown Significant Clinical Benefit In A Phase 2b/3 Trial In Severe Asthma Patients 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 12/10/2014
FDA Grants Breakthrough Therapy Status To Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Ixazomib 12/8/2014
Novartis AG (NVS) Copy Of Amgen (AMGN) Cancer Drug Shows Similar Efficacy 12/8/2014
Shire Release: Phase 3 Guanfacine Hydrochloride Extended Release (GXR) Study Shows Improvement In Core Symptoms Of Attention-Deficit/Hyperactivity Disorder (ADHD) In Children And Adolescents 12/8/2014
Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen (AMGN)'s NEUPOGEN® 12/8/2014
Novartis AG (NVS) Fingolimod Ph3 Trial In PPMS Fails To Meet Primary Goal 12/3/2014
Novartis AG (NVS) Flu Vaccine FLUAD Suspended Following 13 Reported Deaths 12/3/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Mylan Inc. (MYL), Gilead Sciences, Inc. (GILD) Ink Agreement Covering Non-Exclusive TAF Rights 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
AEterna Zentaris (AEZS) And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China 12/1/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Positive Regulatory Feedback From European Medicines Agency On Advancing ICT-107 To Phase 3 Program 12/1/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Brodalumab Phase 3 Study Met All Primary Endpoints Against Johnson & Johnson (JNJ)'s Stelara 11/26/2014
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets FDA Breakthrough Therapy Designation 11/24/2014
Onxeo Announces Positive DSMB Recommendation For Its Phase 3 Trial With Livatag® In Primary Liver Cancer 11/24/2014
Top 10 Countries For Diabetes Clinical Research 11/21/2014
Celgene (CELG) Receives Positive CHMP Opinion For OTEZLA (apremilast), The First Oral PDE4 Inhibitor For The Treatment Of Patients With Psoriasis And Psoriatic Arthritis 11/21/2014
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/20/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase 3 Study Of Once Daily Envarsus® XR Demonstrating Non-Inferiority Vs. Twice-Daily Tacrolimus In De Novo Kidney Transplant Patients 11/17/2014
Amgen (AMGN) And AstraZeneca PLC (AZN) Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 11/12/2014
FDA Grants QIDP Fast-Track Designation To RedHill Biopharma Ltd. (RDHL)'s Phase 3 H. Pylori Drug RHB-105 11/10/2014
Genmab A/S (GEN.CO) Announces Additional Data From Phase 3 Study Of Ofatumumab As Maintenance Therapy For Relapsed CLL 11/6/2014
Nine Out Of 10 Lost Weight With Novo Nordisk A/S (NVO)'s Obesity Drug Liraglutide 11/5/2014
AstraZeneca PLC (AZN) And Pharmacyclics, Inc. (PCYC) Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers 11/5/2014
Celsion Corporation (CLSN) Receives VHP Approval To Initiate OPTIMA Study In Europe 11/5/2014
Novo Nordisk A/S (NVO) Release: New Phase 3a Data Demonstrate That 9 Out Of 10 Adults With Obesity Lost Weight With Liraglutide 3 Mg And Clinical Trial Completers Lost An Average Of 9.2% 11/4/2014
Sanofi Pasteur (SASY.PA)'s Investigational Dengue Vaccine Hits Main Goal Showing Efficacy In Phase 3 Trial 11/4/2014



//-->